retatrutide ema approval status 2025 π A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with type 2 diabetes, a new phase 3 trial shows. is part of an emerging generation Retatrutide Weight Loss: Clinical Data
Description
Right ventricular (RV) dysfunction is a critical complication of pulmonary hypertension (PH) with limited treatment strategies
95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)
Saxenda is manufactured by Novo Nordisk and is specifically designed for weight management
It is classified as a reference and research-grade reagent for laboratory use only
